PerkinElmer

PerkinElmer, Inc. engages in the provision of products, services, and solutions for diagnostics, food, environmental, life sciences, and applied markets. It operates through the following segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment consists of technologies that help life sciences researchers better understand diseases and develop treatments. The Diagnostics segment offers instruments, reagents, assay platforms, and software to hospitals, medical labs, clinicians, and medical research professionals to help improve the health of families. The company was founded by Richard Scott Perkin and Charles W. Elmer on April 19, 1937, and is headquartered in Waltham, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Revvity, Inc. provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. It focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, and informatics. With a global network and localized agility, the company serves a diverse range of organizations from pharmaceutical and biotech to clinical labs, academia, and governments. It is headquartered in Waltham, MA.

QuidelOrtho Corp

We believe that there are other stocks in the healthcare sector that are currently better valued than Aboott Laboratories. Abbott's current price-to-operating income ratio (P/EBIT) of 30x is much higher than levels of under 12x for PerkinElmer, and 4x for Quidel.

These Stocks Are Better Priced Compared To Abbott

PerkinElmer is a healthcare solutions company with a long-track record of market beating returns. It's benefitted from COVID-19 testing, and is exploring promising new growth avenues.

Why PerkinElmer Is A SWAN Stock You Can Buy Today

WALTHAM, Mass.--(BUSINESS WIRE)--Company provides its PhenoVue™ Cell Painting Kits to JUMP-CP consortium led by Broad Institute to help create world's largest cell painting data set.

PerkinElmer Supports JUMP-CP Consortium Creating World's Largest, Public Cell Painting Dataset

Check Point Software Technologies

Domino's Pizza

Snap-on

VeriSign

According to the GuruFocus discounted cash flow calculator as of June 4, the following companies have a high margin of safety and have grown their margins over a 10-year period.

5 Undervalued Stocks With Profitable Business

PerkinElmer (PKI) reported earnings 30 days ago. What's next for the stock?

PerkinElmer (PKI) Up 1.9% Since Last Earnings Report: Can It Continue?

PerkinElmer's (PKI) COVID-19 Lighthouse Laboratory contract extended through March 2022 to align with NHS Test and Trace's testing strategy.

PerkinElmer (PKI) Gets COVID-19 Solutions Contract Extension

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

Here's How Much a $1000 Investment in PerkinElmer Made 10 Years Ago Would Be Worth Today

Salesforce

While few investors or traders pay much attention to monthly charts, the Viper Report's Tom Aspray, runs monthly as well as weekly scans to find the best opportunities.

Two Stocks On My Monthly Buy List

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced that its contract to operate the NHS Test and Trace Newport Lighthouse laboratory has been extended through March 2022. A collaboration between PerkinElmer and NHS Test and Trace, the COVID-19 Lighthouse laboratory in Newport, South Wales, plays a pivotal role in supporting the UK government's efforts to tackle COVID-19. Since being brought online in October 2020, t

Welsh Lighthouse Laboratory Extends Contract with PerkinElmer for its COVID-19 Solutions

AbbVie

Owens & Minor

A tax refund is a great opportunity to invest in these three medical companies that have solid revenue growth ahead.

3 Strong Stocks for Your Income Tax Return

PerkinElmer's (PKI) test kit, which is currently being used in an investigative study, is aimed at accelerating the vaccine development and treatments against COVID-19.

PerkinElmer's (PKI) COVID-19 Test Kit Part of Investigative Study

An agreed takeover offer worth £110mln from PerkinElmer made Immunodiagnostic Systems Holdings PLC (LON:IDH) one of the week's top risers. The shares rose 47% to 375p, a shade below the 382p a share offer price.

Small cap movers: Immunodiagnostic Systems succumbs to agreed bid from PerkinElmer

PerkinElmer (PKI) enters into an agreement to acquire IDS, which will enable the former to grow its overall Diagnostics business, particularly its immunodiagnostics unit.

PerkinElmer (PKI) to Boost Immunodiagnostics Unit With Buyout

OXFORD, United Kingdom and MARLBOROUGH, Mass., May 18, 2021 (GLOBE NEWSWIRE) -- Oxford Immunotec, a global, high-growth diagnostics company part of PerkinElmer, today announced that its T-SPOT® Discovery SARS-CoV-2 kit is being used for T cell testing in the UK COVID-19 Human Challenge Study, a national collaboration including the UK government, the NHS, academia and the private sector. The study is funded by the Department of Business, Energy, and Industrial Strategy (BEIS) through the UK Vaccines Taskforce and is being delivered through a partnership between government, hVIVO (part of Open Orphan plc), Imperial College London, and The Royal Free London NHS Foundation Trust.

Oxford Immunotec's T-SPOT Discovery SARS-CoV-2 Test is Used in the UK COVID-19 Human Challenge Study to Investigate the T Cell Response to SARS-CoV-2 Infection

PerkinElmer Inc (NYSE: PKI) has agreed to acquire the U.K.-listed Immunodiagnostic Systems Holdings Plc's (IDS) in an all-cash transaction of approximately $155 million (£110 Million). The transaction has a total enterprise value of approximately $124 million (£88 Million) and is expected to close early in the third quarter of 2021.

PerkinElmer To Acquire UK-Based In-Vitro Diagnostics Company For $155M

Immunodiagnostic Systems Holdings PLC (LON:IDH) shares jumped 45% to 370p after it agreed to a 382p per share offer from PerkinElmer. The acquisition values Immunodiagnostic Systems at about £110mln, and implies an enterprise value (i.e.

Immunodiagnostics Systems succumbs to offer from PerkinElmer

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI) (“PerkinElmer”) and Immunodiagnostic Systems Holdings PLC (LSE: IHS) (“IDS”) are pleased to announce that they have reached an agreement on the terms of a recommended all cash offer whereby PerkinElmer will acquire IDS for approximately $155 million (£110 Million). The transaction has a total enterprise value of approximately $124 million (£88 Million) and is expected to close early in the third quarter of 2021, subject to approvals

PerkinElmer to Acquire In-Vitro Diagnostics Company Immunodiagnostic Systems Holdings PLC

PerkinElmer (PKI) enters into an agreement to acquire Nexcelom that will enable the former to boost its efforts when it comes to solutions for drug discovery.

PerkinElmer (PKI) Boosts Cell Biology Portfolio With Buyout

PerkinElmer Inc (NYSE: PKI) has agreed to acquire privately-held Nexcelom Bioscience, a provider of instruments, workstations, assays, cell reagents & consumables with application in the development of cell and gene and immuno-oncology therapies, virology drugs, and vaccines. The deal value of $260 million will be paid using cash on hand.

PerkinElmer Expands Into Cell Biology With $260M Nexcelom Bioscience Acquisition

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer Expands Cell Biology Leadership with Agreement to Acquire Nexcelom Bioscience

PerkinElmer Expands Cell Biology Leadership with Agreement to Acquire Nexcelom Bioscience

OXFORD, United Kingdom and MARLBOROUGH, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Oxford Immunotec a global, high-growth diagnostics company part of PerkinElmer, announced that its T-SPOT®.COVID test will be used for T cell testing in the COV-AD (COVID infection in patients with Antibody Deficiency) study in collaboration with the University of Birmingham. The study will monitor the clinical course of SARS-CoV-2 infection and the immunological response of patients to vaccination. The study will collect samples from 13 sites around the UK.

Oxford Immunotec's T-SPOT.COVID Test is Used in the COV-AD Clinical Study to Investigate the Immunological Response to SARS-CoV-2 Infection in Patients with Primary and Secondary Antibody Deficiency

PerkinElmer (PKI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

PerkinElmer (PKI) Moves 6.9% Higher: Will This Strength Last?

PerkinElmer, Inc. (PKI) CEO Prahlad Singh on Q1 2021 Results - Earnings Call Transcript

Shares of PerkinElmer (NYSE:PKI) increased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 455.22% year over year to $3.72, which beat the estimate of $3.07.

PerkinElmer: Q1 Earnings Insights

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will host a virtual Investor and Analyst Day on Thursday, June 24, 2021 from 8:30 a.m. to 12:00 p.m. ET. The virtual format will feature presentations by members of PerkinElmer's senior management team including an update on business conditions and the meeting will conclude with a Q&A session. A live webcast will be available to regi

News for PerkinElmer Stock (PKI)